Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18 F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
Chengcheng GongCheng LiuZhonghua TaoJian ZhangLeiping WangJun CaoYannan ZhaoYizhao XieXichun HuZhongyi YangBi-Yun WangPublished in: Cancers (2022)
F-FDG uptake could predict the treatment outcome of pyrotinib in patients with HER2-positive MBC, which provide practically applicable methods to assess tumor heterogeneity and guidance for treatment decisions.